Role of intracoronary SNP (sodium nitroprusside) in management of slow flow/no flow during AMI.
I am planning a observational study on management of coronary slow flow with use of intracoronary SNP. Any suggestions in making a protocol?
el objetivo de su administración es lograr el mejor flujo epicárdico (TIMI y TFC) y miocárdico (TMP), dado que es un donante de óxido nítrico que no requiere metabolismo y que induce dilatación de los vasos de conductancia, se ha probado con bolos repetidos de 100 μg (hasta 700 μg) con jeringas de 3 ml (alta velocidad de inyección) mejorando el TIMI.
following article may be helpful:
BMC Cardiovascular Disorders (Impact Factor: 1.5). 12/2015; 15(1). DOI: 10.1186/s12872-015-0004-6
Planning to do a head to head comparision of SNP and Nikoran for no flow after PCI.The incidence of no flow in our center is around 5-15 %..so planning roughly 50 case in each study arm.
Is there any upper limit for administering SNP/Nikoran as both the drugs are recommended as level II evidence for no flow/slow flow in the ACC guidelines
- Badges
- Science topic
- Similar topics
- Chemistry
- Pharmacology
- Medical Pharmacology
- Clinical Pharmacology